Physician profile
Debra B Luftman
NPI 1063524270
$3,619.10
in general payments reported to CMS, 2019-2025
32 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $553 · 2021: $165 · 2022: $202 · 2023: $703 · 2024: $567 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.96 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.30 | 2020-2025 | |
| Galderma Laboratories, L.P. | $500.08 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $439.98 | 2019-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $282.12 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $192.22 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $174.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $142.45 | 2023 | Sotyktu |
| Biofrontera INC. | $139.83 | 2019 | |
| Amgen INC. | $137.30 | 2022-2025 | Otezla, Otezla |
| Almirall LLC | $99.95 | 2023-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $98.18 | 2019-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $92.99 | 2020-2024 | Ilumya |
| Journey Medical Corporation | $68.70 | 2023-2024 | |
| Organon LLC | $59.70 | 2025 | Vtama |
| Epi Health, LLC | $53.15 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $48.93 | 2023 | Vtama |
| Incyte Corporation | $47.51 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $43.04 | 2025 | Zoryve |
| Janssen Biotech, INC. | $41.15 | 2022-2024 | Tremfya |
| Organogenesis INC. | $40.94 | 2019-2024 | |
| Medtronic, INC. | $37.87 | 2023 | Sinuva |
| Genzyme Corporation | $37.19 | 2022-2023 | |
| Revance Therapeutics, INC. | $33.17 | 2024 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $25.00 | 2020 | |
| Pfizer INC. | $23.53 | 2020 | |
| Stryker Corporation | $21.63 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.98 | 2022 | |
| Merck Sharp & Dohme LLC | $19.66 | 2019 | |
| Allergan, INC. | $19.17 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $16.09 | 2025 | Genadur, Clindacin Etz |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Luftman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.